Type and Duration of Dual Antiplatelet Therapy in Complex Percutaneous Coronary Intervention

Type and Duration of Dual Antiplatelet Therapy in Complex Percutaneous Coronary Intervention

Complex percutaneous coronary intervention (PCI) patients are a high-risk population for ischemic complications. Antiplatelet therapy in such patients remains controversial, as the beneficial effects of more potent agents use or prolonged dual antiplatelet treatment (DAPT) on atherothrombotic compli...

Full description

Bibliographic Details
Main Authors:	Dimitrios Alexopoulos, Charalampos Varlamos, Despoina-Rafailia Benetou
Format:	Article
Language:	English
Published:	Radcliffe Medical Media 2020-11-01
Series:	US Cardiology Review
Online Access:	https://www.uscjournal.com/articles/type-and-duration-of-dual-antiplatelet-therapy

Similar Items

Antithrombotics in Complex Percutaneous Coronary Interventions: Type and Duration of Treatment
by: Despoina-Rafailia Benetou, et al.
Published: (2021-10-01)

Antithrombotic Therapy in Complex Percutaneous Coronary Intervention Patients Requiring Chronic Anticoagulation
by: Despoina-Rafailia Benetou, et al.
Published: (2021-05-01)

Left Main Disease and Bifurcation Percutaneous Coronary Intervention: Focus on Antithrombotic Therapy
by: Charalampos Varlamos, et al.
Published: (2021-06-01)

Delayed percutaneous coronary intervention for an extensive iatrogenic left main coronary artery dissection: a case report
by: Charalampos Varlamos, et al.
Published: (2022-12-01)

Antithrombotic Therapy in Chronic Total Occlusion Interventions
by: Iosif Xenogiannis, et al.
Published: (2021-05-01)

Safety and efficacy of shortened dual antiplatelet therapy after complex percutaneous coronary intervention: A systematic review and meta-analysis
by: Anastasios Apostolos, et al.
Published: (2023-05-01)

Shortened Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Contemporary Clinical Review
by: Kevin S Tang, et al.
Published: (2023-12-01)

Extended Duration of Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long?
by: Charles E. Howard, et al.
Published: (2019-10-01)

The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention
by: A. S. Tereshchenko, et al.
Published: (2019-05-01)

Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01)

Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Short Is Too Short?
by: Philipp Mourikis, et al.
Published: (2023-01-01)

Thirty-Days versus Longer Duration of Dual Antiplatelet Treatment after Percutaneous Coronary Interventions with Newer Drug-Eluting Stents: A Systematic Review and Meta-Analysis
by: Grigorios Tsigkas, et al.
Published: (2023-02-01)

DURATION OF DUAL ANTIPLATELET THERAPY
by: O. L. Barbarash
Published: (2016-07-01)

Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis
by: Kevin R. Bainey, et al.
Published: (2023-01-01)

Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review
by: Mohamed Farag, et al.
Published: (2022-10-01)

Guided antiplatelet therapy in patients undergoing percutaneous coronary intervention
by: Marco Cattaneo
Published: (2023-06-01)

The Optimal Strategy of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stent
by: Mengjin Hu, et al.
Published: (2022-07-01)

Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
by: Jialun Han, et al.
Published: (2023-03-01)

From Coronaries to Cirrhosis: The Role of Percutaneous Coronary Intervention and Dual Antiplatelet Therapy in End-Stage Liver Disease
by: Taylor C. Remillard MD, et al.
Published: (2021-11-01)

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how
by: Marie Muthspiel, et al.
Published: (2022-11-01)

Cost analysis of dual antiplatelet therapy with prasugrel and ticagrelor in patients with acute coronary syndrome after percutaneous coronary intervention
by: I. N. Dyakov, et al.
Published: (2020-09-01)

Meta-analysis of Unguided Deescalation of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
by: Mohamed M. G. Mohamed, et al.
Published: (2022-04-01)

Duration and clinical outcomes of dual antiplatelet therapy following percutaneous coronary intervention for acute coronary syndrome: A multicentre “real-world practice” registry-based study
by: Carlos E. Vergara-Uzcategui, et al.
Published: (2023-04-01)

Income and antiplatelet adherence following percutaneous coronary intervention
by: Anna R. LaRosa, et al.
Published: (2022-09-01)

Efficacy and Safety of Thirty-Day Dual-Antiplatelet Therapy Following Complex Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
by: Anastasios Apostolos, et al.
Published: (2024-01-01)

Shortenеd and prolonged dual antiplatelet therapy after percutaneous coronary interventions – why, when and how?
by: P. Gatzov
Published: (2022-09-01)

Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?
by: T. M. Uskach, et al.
Published: (2020-12-01)

Ultrasound-Guided Femoral Vascular Access for Percutaneous Coronary and Structural Interventions
by: Iosif Xenogiannis, et al.
Published: (2023-06-01)

Efficiency and safety of various dual antiplatelet therapy strategies in patients undergoing percutaneous coronary intervention due to myocardial infarction
by: S. B. Aksentiev, et al.
Published: (2021-08-01)

Antiplatelet medications in acute coronary syndromes and percutaneous coronary interventions: focus on tirofiban
by: T. A. Batyraliev, et al.
Published: (2008-12-01)

Risk of Postdischarge Bleeding From Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Among US Black and White Adults
by: Brittain Heindl, et al.
Published: (2022-09-01)

Effects of dual antiplatelet therapy de-escalation on the prognosis of acute coronary syndrome patients at high risk of ischemia who underwent percutaneous coronary intervention
by: Jingyao Wang, et al.
Published: (2024-03-01)

The Impact of Patient Adherence to Dual Antiplatelet Medication Following Percutaneous Coronary Intervention on the Occurrence of Adverse Cardiovascular Events
by: Mansurova JA, et al.
Published: (2024-02-01)

Effectiveness of dual antiplatelet de-escalation therapy on the prognosis of patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention
by: Zhigang Zhao, et al.
Published: (2023-03-01)

De-escalation versus standard dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
by: Chen Guo, et al.
Published: (2020-01-01)

What is the Optimal Duration of Dual Antiplatelet Therapy After Stenting?
by: Udaya S. Tantry, et al.
Published: (2016-04-01)

Individualization of Duration of Dual Antiplatelet Therapy after Coronary Stenting: A Comprehensive, Evidence-Based Review
by: Gabriele Carciotto, et al.
Published: (2023-11-01)

Early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk
by: O. V. Averkov
Published: (2021-02-01)

Use of Optical Coherence Tomography in MI with Non-obstructive Coronary Arteries
by: Grigoris Karamasis, et al.
Published: (2022-05-01)

Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention
by: Francesco Pelliccia, et al.
Published: (2022-06-01)